Have a feature idea you'd love to see implemented?
Let us know!
BIVI Biovie Inc
Price (delayed)
$3.11
Market cap
$55.26M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.2
Enterprise value
$38.95M
BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of
Highlights
BIVI's quick ratio has soared by 82% YoY and by 15% from the previous quarter
BIVI's debt has shrunk by 70% YoY and by 39% QoQ
BIVI's equity has surged by 86% year-on-year but it is down by 9% since the previous quarter
Key stats
What are the main financial stats of BIVI
Market
Valuations
Earnings
Shares outstanding
17.77M
Market cap
$55.26M
Enterprise value
$38.95M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.76
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$23.42M
EBITDA
-$23.12M
Free cash flow
-$19.35M
Per share
Balance sheet
Liquidity
EPS
-$5.2
Free cash flow per share
-$3.02
Book value per share
$1.77
Revenue per share
$0
TBVPS
$3.21
Total assets
$21.24M
Total liabilities
$7.17M
Debt
$3.72M
Equity
$14.07M
Working capital
$13.31M
Debt to equity
0.26
Current ratio
2.95
Quick ratio
2.93
Net debt/EBITDA
0.71
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-107.4%
Return on equity
-191.3%
Return on invested capital
N/A
Return on capital employed
-162.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BIVI stock price
How has the Biovie stock price performed over time
Intraday
-7.44%
1 week
-2.2%
1 month
18.25%
1 year
-92.83%
YTD
-75.32%
QTD
159.17%
Financial performance
How have Biovie's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$25.43M
Net income
-$25.56M
Gross margin
N/A
Net margin
N/A
The net income is up by 49% year-on-year and by 20% since the previous quarter
The company's operating income rose by 46% YoY and by 21% QoQ
Growth
What is Biovie's growth rate over time
Valuation
What is Biovie stock price valuation
P/E
N/A
P/B
1.76
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 64% YoY and by 29% from the previous quarter
BIVI's equity has surged by 86% year-on-year but it is down by 9% since the previous quarter
The price to book (P/B) is 85% lower than the 5-year quarterly average of 11.8 and 27% lower than the last 4 quarters average of 2.4
Efficiency
How efficient is Biovie business performance
BIVI's ROE is up by 33% YoY and by 28% QoQ
The company's return on assets rose by 20% YoY and by 17% QoQ
Dividends
What is BIVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BIVI.
Financial health
How did Biovie financials performed over time
Biovie's total assets is 196% more than its total liabilities
BIVI's quick ratio has soared by 82% YoY and by 15% from the previous quarter
Biovie's current ratio has surged by 72% YoY and by 15% QoQ
BIVI's debt is 74% lower than its equity
BIVI's equity has surged by 86% year-on-year but it is down by 9% since the previous quarter
BIVI's debt to equity has plunged by 84% YoY and by 33% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.